复星医药(02196)：复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款

智通财经网04-29

智通财经APP讯，复星医药(02196)发布公告，为满足复星凯特生物科技有限公司(以下简称“复星凯特”)经营计划及资金需求，拟提请该公司股东大会批准控股子公司上海复星医药产业发展有限公司(以下简称“复星医药产业”)与复星凯特的另一方股东 Kite Pharma,Inc.(以下简称“Kite Pharma”)根据各自所持复星凯特的股权比例向复星凯特续展及新增提供总额不超过等值 6700 万美元(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2431883946?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-04-29 18:46","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2431883946","market":"sh","top_or_hot":-1,"title":"复星医药(02196)：复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，复星医药(02196)发布公告，为满足复星凯特生物科技有限公司(以下简称“复星凯特”)经营计划及资金需求，拟提请该公司股东大会批准控股子公司上海复星医药产业发展有限公司(以下简称“复星医药产业”)与复星凯特的另一方股东  Kite Pharma,Inc.(以下简称“Kite Pharma”)根据各自所持复星凯特的股权比例向复星凯特续展及新增提供总额不超过等值 6700  万美元(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1114612.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196)：复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196)：复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-29 18:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1114612.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复星医药(02196)发布公告，为满足复星凯特生物科技有限公司(以下简称“复星凯特”)经营计划及资金需求，拟提请该公司股东大会批准控股子公司上海复星医药产业发展有限公司(以下简称“复星医药产业”)与复星凯特的另一方股东  Kite Pharma,Inc.(以下简称“Kite Pharma”)根据各自所持复星凯特的股权比例向复星凯特续展及新增提供总额不超过等值 6700  万美元(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1114612.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1114612.html","article_id":"2431883946","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431883946","pubTimestamp":1714387592,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"复星医药(02196)发布公告，为满足复星凯特生物科技有限公司(以下简称“复星凯特...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","BK0175":"白马股","BK0096":"民营医院","02196":"复星医药","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造","BK0012":"证金概念","BK0183":"MSCI概念","KITE":"Kite Pharma","BK0187":"一线龙头","BK0060":"抗癌","BK0196":"行业龙头"},"translate_title":"Fosun Pharma (02196): Fosun Pharma Industry and Kite Pharma intend to renew and provide new loans with a total amount of no more than US $67 million equivalent to Fosun Kite according to their respective shareholding ratios","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1,"KITE":1},"content_text":"智通财经APP讯，复星医药(02196)发布公告，为满足复星凯特生物科技有限公司(以下简称“复星凯特”)经营计划及资金需求，拟提请该公司股东大会批准控股子公司上海复星医药产业发展有限公司(以下简称“复星医药产业”)与复星凯特的另一方股东  Kite Pharma,Inc.(以下简称“Kite Pharma”)根据各自所持复星凯特的股权比例向复星凯特续展及新增提供总额不超过等值 6700  万美元(含本数)的借款(包括直接借款或委托贷款等形式，下同)，其中，复星医药产业拟按所持股权比例(即 50%)向其提供不超过等值 3350  万美元(含本数)借款。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431883946"}